Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases

Investigative Radiology

Volumn 48, Issue 11, 2013, Pages 787-794

  Morsbach, Fabian ^a   Pfammatter, Thomas ^a   Reiner, Caecilia S ^a   Fischer, Michael A ^a   Sah, Bert Ram ^b   Winklhofer, Sebastian ^a   Klotz, Ernst ^c   Frauenfelder, Thomas ^a   Knuth, Alexander ^b   Seifert, Burkhardt ^d   Schaefer, Niklaus ^b   Alkadhi, Hatem ^a  

^a University Hospital Zurich Institut fur Diagnostische Radiologie   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c SIEMENS AG   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

computed tomography; liver neoplasm; liver perfusion; RECIST; transarterial radioembolization

Indexed keywords

MICROSPHERE; YTTRIUM 90;

ADULT; AGED; AREA UNDER THE CURVE; ARTERY PERFUSION; ARTICLE; ARTIFICIAL EMBOLISM; CALCULATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC PERFUSION IMAGING; COMPUTER ASSISTED TOMOGRAPHY; CONVENTIONAL ANGIOGRAPHY; FEMALE; FOLLOW UP; HEALTH; HUMAN; LIVER METASTASIS; LIVER SURGERY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; TRANSARTERIAL RADIOEMBOLIZATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

ANGIOGRAPHY; ARTERIES; CONTRAST MEDIA; FEMALE; HUMANS; IOHEXOL; LIVER; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84885420296     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31829810f7     Document Type: Article

References (43)

1. Jakobs TF, Hoffmann RT, Poepperl G, et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol. 2007;17:1320-1330.
2. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepato-cellular carcinoma with intrahepatic 90-microspheres. J Nucl Med. 2000; 41:1673-1681.
3. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687-3694.
4. Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 micro-sphere therapy. Phys Med Biol. 2000;45:1023-1033.
5. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552-1563.
6. Yorke ED, Jackson A, Fox RA, et al. Can current models explain the lack of liver complications in Y-90 microsphere therapy? Clin Cancer Res. 1999;5: 3024s-3030s.
7. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepa-tocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
8. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-1720.
9. Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2012;35:1066-1073.
10. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-The-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol. 2006;17:1425-1439.
11. Ray CE Jr, Battaglia C, Libby AM, et al. Interventional radiologic treatment of hepatocellular carcinomaVa cost analysis from the payer perspective. J Vasc Interv Radiol. 2012;23:306-314.
12. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepa-tocellular carcinoma with use of 90-microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639.
13. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205-213.
14. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74: 1494-1500.
15. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90-resin micro-spheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:792-800.
16. Sato KT, Omary RA, Takehana C, et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol. 2009;20:1564-1569.
17. 99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT). BMC Nucl Med. 2005;5:7.
18. Goh V, Halligan S, Wellsted DM, et al. Can perfusion CTassessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent met-astatic disease? A pilot study. Eur Radiol. 2009;19:79-89.
19. Fournier LS, Oudard S, Thiam R, et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology. 2010;256:511-518.
20. Ng CS, Wang X, Faria SC, et al. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010;194: 166-171.
21. Kan Z, Kobayashi S, Phongkitkarun S, et al. Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. Radiology. 2005;237:144-150.
22. Choi SH, Chung JW, Kim HC, et al. The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest Radiol. 2010;45:427-436.
23. Reiner CS, Roessle M, Thiesler T, et al. Computed tomography perfusion imaging of renal cell carcinoma: systematic comparison with histo-pathological angiogenic and prognostic markers. Invest Radiol. 2013;48: 183-191.
24. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23.
25. Salem R, Thurston KG. Radioembolization with 90-ttrium microspheres: a state-of-The-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278.
26. Reiner CS, Goetti R, Burger IA, et al. Liver perfusion imaging in patients with primary and metastatic liver malignancy: prospective comparison between 99mTc-MAA spect and dynamic CT perfusion. Acad Radiol. 2012;19: 613-621.
27. Brix G, Lechel U, Petersheim M, et al. Dynamic contrast-enhanced CT studies: balancing patient exposure and image noise. Invest Radiol. 2011;46:64-70.
28. Goetti R, Reiner CS, Knuth A, et al. Quantitative perfusion analysis of malignant liver tumors: dynamic computed tomography and contrast-enhanced ultrasound. Invest Radiol. 2012;47:18-24.
29. Goetti R, Leschka S, Desbiolles L, et al. Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Invest Radiol. 2010;45:419-426.
30. Huda W, Ogden KM, Khorasani MR. Converting dose-length product to effective dose at CT. Radiology. 2008;248:995-1003.
31. Bledin AG, Kim EE, Chuang VP, et al. Changes of arterial blood flow patterns during infusion chemotherapy, as monitored by intra-arterially injected tech-netium 99m macroaggregated albumin. Br J Radiol. 1984;57:197-203.
32. Lau WY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82:401-407.
33. Cosimelli M, Mancini R, Carpanese L, et al. Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer. Expert Opin Ther Targets. 2012;16(suppl 2):S11-S16.
34. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
35. Saddi KA, Chefd'hotel C, Cheriet F. Large deformation registration of contrast-enhanced images with volume-preserving constraint. In: Pluim JPW, Reinhardt JM, eds. Medical Imaging 2007: Image Processing. Proceedings of the SPIE; 2007:6512. Article id. 651203.
36. Miles KA, Hayball MP, Dixon AK. Functional images of hepatic perfusion obtained with dynamic CT. Radiology. 1993;188:405-411.
37. Blomley MJ, Coulden R, Dawson P, et al. Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr. 1995;19:424-433.
38. Tsushima Y, Funabasama S, Aoki J, et al. Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data. Acad Radiol. 2004;11:215-223.
39. Tochetto SM, Rezai P, Rezvani M, et al. Does multidetector CT attenuation change in colon cancer liver metastases treated with 90-help predict metabolic activity at FDG PET? Radiology. 2010;255:164-172.
40. Gaba RC, Jin B, Wang D, et al. Locoregional chemoembolic delivery: prediction with transcatheter intraarterial perfusion MRI. AJR Am J Roentgenol. 2012;198:1196-1202.
41. Goh V, Halligan S, Hugill JA, et al. Quantitative assessment of colorectal cancer perfusion using MDCT: inter-and intraobserver agreement. AJR Am J Roentgenol. 2005;185:225-231.
42. Winterdahl M, Sorensen M, Keiding S, et al. Hepatic blood perfusion estimated by dynamic contrast-enhanced computed tomography in pigs: limitations of the slope method. Invest Radiol. 2012;47:588-595.
43. Goh V, Halligan S, Bartram CI. Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable? Radiology. 2007;242:777-782.